Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.
about
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparumArtesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malariaUsing genetic methods to define the targets of compounds with antimalarial activityAntimalarial drug discovery - approaches and progress towards new medicines.Antiparasitic therapyPyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trialA head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trialPlasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia.Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali.In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.Pyronaridine: a new 'old' drug on the verge of entering the antimalarial armamentarium.A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmissionRandomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo.PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisininMalaria: an update on current chemotherapy.Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines.Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study.Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia.Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridineDrug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers.Improving malaria control in West Africa: interruption of transmission as a paradigm shift.Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency.Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania.Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance.Combination therapy--a way to forestall artemisinin resistance and optimize uncomplicated malaria treatment.Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impactMalaria drug resistance: new observations and developments.The global pipeline of new medicines for the control and elimination of malariaReview of pyronaridine anti-malarial properties and product characteristics.Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridinePyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trialPopulation Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients.Newer approaches to malaria controlA Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and AfricaEfficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia.
P2860
Q21032477-6DA6835B-97A8-4C3C-B969-D8DE80A17D78Q24198103-677E40B0-2B75-47C1-BABF-1F722A9F52CEQ27014788-E638CEE3-5624-4E8B-8184-0B7F3CC09C4CQ27693245-5264F4C4-15B8-4096-8A88-B890C4ED6AA6Q28239164-7B685217-1B10-4030-A2FC-25D34EF8D38BQ28476754-39F62656-A430-4377-B882-63286D59FB63Q28477853-55C6983D-5C06-47BA-8919-A9169244D55DQ30240158-B4120C6A-5FFC-4626-8CB8-78A2F1437D6BQ30592761-139ABDD2-B149-4312-8802-41838EE273B2Q30850979-AB07CA03-CC01-4C61-85F5-C26B12B85347Q33704762-F694FCA1-5ADD-4AD5-9743-0C66209F4CBFQ33876781-75F82681-BCFC-4D99-961D-F985FD89D84CQ34020818-3A1C1853-43C5-4CDF-BE6C-9AD72DF729D3Q34057403-4193B326-5019-4314-8A3C-61BE09108F84Q34129977-2852ACF4-A6E4-4081-A91F-DE24DACD7219Q34433106-D716842E-AE9E-4290-8B10-80F5999779E9Q34478487-4CAEF80C-1E13-4D33-8B17-E33D8C2CF1FBQ34503134-58E63193-953B-4D99-98CB-CF3CAE1046E1Q35068138-041F86B5-0A14-4AD4-BA6F-DA288C6AAB56Q35186075-2E3A3807-23DC-411E-A6F4-EBAE9100BD64Q35224221-182DBD42-CB96-4756-A8B8-ACCE3D899A3BQ35573542-82F2B2D5-EE7E-4B65-9C72-27C4C420F946Q35771822-F44E8883-A3D9-40D7-B4BE-8A048B5D9C03Q35803321-0C4ED3E6-EC3B-463C-947F-7D1ABB4352FBQ35820930-A27302C1-58B9-4B64-99CC-1A3CE615C0B0Q35833995-8666AE37-BE7A-4517-96D6-98F2F8113816Q35834198-105E86C3-4178-4ABE-A0CF-EA0791963ECFQ35859975-737E59D7-86E8-42E6-901E-27DEFF528D73Q36017687-445A94C3-8E53-4E7C-9E76-B9E8C1B90F58Q36080127-7CEE7E0C-CC42-437D-8082-4E7989588F55Q36190902-8DC8577A-B3F6-4BBF-AA31-38E835BA26AAQ36320249-62CC8F28-9D31-4E44-B471-F4C7E01C6354Q36353708-2DB7850A-AD4D-4E5F-B08A-05C73BBD0851Q36501878-E874889D-57A6-4CB1-AA5F-D56C384A39D1Q36560464-5BE5E1EB-1B9C-49B7-BCB4-CCDB567D53CAQ36594406-95828E69-9F5E-4562-B298-48976DBDC6FFQ36644620-5E399C4B-297A-4AC6-8FC9-169870033D6AQ36671591-65B47A31-5DE2-4386-9106-ED40C67AF780Q36715829-05E02701-236F-4297-BD13-85E1ED201859Q37023329-FCD48513-A475-4969-A776-DA34B1906DF2
P2860
Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Efficacy and safety of a fixed ...... domised non-inferiority trial.
@en
Efficacy and safety of a fixed ...... domised non-inferiority trial.
@nl
type
label
Efficacy and safety of a fixed ...... domised non-inferiority trial.
@en
Efficacy and safety of a fixed ...... domised non-inferiority trial.
@nl
prefLabel
Efficacy and safety of a fixed ...... domised non-inferiority trial.
@en
Efficacy and safety of a fixed ...... domised non-inferiority trial.
@nl
P2093
P50
P921
P1433
P1476
Efficacy and safety of a fixed ...... domised non-inferiority trial.
@en
P2093
Antoinette K Tshefu
Chang Sik Shin
Dorina G Bustos
George Bedu-Addo
Isabelle Borghini-Fuhrer
Kirana M Bhatt
Oumar Gaye
Pyronaridine-artesunate Study Team
Ricardo Thompson
Sanie S S Sesay
P304
P356
10.1016/S0140-6736(10)60322-4
P407
P577
2010-04-01T00:00:00Z